Company profile: Pierian
1.1 - Company Overview
Company description
- Provider of genomic SaaS solutions, a CAP and CLIA accredited laboratory, and a shared knowledgebase to enable physicians in the laboratory and clinic to diagnose and treat cancer and other complex diseases. Offerings include the Clinical Genomics Workspace, a knowledgebase with over 350,000 inferencing rules, professional services, IVD partnerships, EMR/LIS/EDW integration, and wet lab workflow guidance.
Products and services
- Knowledgebase: A rule-based, shared database with over 350,000 inferencing rules and genomic data to drive accurate variant interpretation within clinical reporting workflows
- Clinical Genomics Workspace: A SaaS-based software platform that analyzes, interprets, and reports patient genomic data, architected for clinical lab and clinic workflows to support cancer and complex disease decision-making
- Data Integration: Enterprise-grade integration services connecting genomic workflows to EMR, LIS, and EDW systems, enabling streamlined data exchange and consolidated reporting across clinical environments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pierian
Omniome
HQ: United States
Website
- Description: Provider of a proprietary DNA sequencing platform delivering high-accuracy short-read sequencing using Sequencing by Binding (SBB) chemistry. Offers the Onso hardware and software system; validated exome/panel sequencing; single-cell RNA-Seq solutions; and tools for cancer research and gene editing, with lower error rates than traditional sequencing by synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omniome company profile →
CTI BioPharma
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer treatment, focused on blood-related cancers. Develops, acquires, and commercializes therapies including Pixantrone (Phase III; non-Hodgkin's lymphoma), Brostallicin (first-line Phase II; sarcoma), and OPAXIO chemotherapeutic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI BioPharma company profile →
Rancho BioSciences
HQ: United States
Website
- Description: Provider of fee-for-service life science data curation and knowledge management, leveraging open-source tools and public domain data for Pharma, non-profit foundations, and academia. Services include data curation, data governance and models, bioinformatics analysis (including genetic variant annotation), workflows and pipelines, knowledge mining, and creation of target profiles to support research and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rancho BioSciences company profile →
Firefly BioWorks
HQ: United States
Website
- Description: Provider of an open platform that enables industrial, academic, and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation, leveraging its core Optical Liquid Stamping technology developed in MIT’s Chemical Engineering Department.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Firefly BioWorks company profile →
Scipher Medicine
HQ: United States
Website
- Description: Provider of a healthcare platform to determine which drug will work best for each patient, offering PrismRA, a blood test that predicts non-response to TNF inhibitors in rheumatoid arthritis; Spectra, a platform that discovers novel drug targets by analyzing patient molecular data and the human interactome; and PrismUC, a diagnostic test for ulcerative colitis utilizing molecular data to guide treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scipher Medicine company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pierian
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pierian
2.2 - Growth funds investing in similar companies to Pierian
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pierian
4.2 - Public trading comparable groups for Pierian
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →